Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-08-28FDA Approved: JENTADUETO — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for JENTADUETO (linagliptin and metformin hydrochloride) submitted by Boehringer Ingelheim Pharm…
-
FDA approval · 2015-08-28FDA Approved: JANUMET XR — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for JANUMET XR, adding an extended-release formulation of sitagliptin and metformin hydrochloride. T…
-
FDA approval · 2015-08-28FDA Approved: ALOGLIPTIN — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for alogliptin submitted by Padagis Israel Pharmaceuticals Ltd.
-
FDA approval · 2015-08-28FDA Approved: KAZANO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for KAZANO (alogliptin and metformin hydrochloride) by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2015-08-28FDA Approved: TRADJENTA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for Tradjenta (linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc. This action approves a s…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-08-28FDA Approved: ALOGLIPTIN AND PIOGLITAZONE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved a supplemental application for a fixed-dose combination of alogliptin benzoate and pioglitazone hydrochloride to treat type 2 d…
-
FDA approval · 2015-08-28FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) submitted by Boehringer Ingelheim Pharmaceuticals, …
-
CLINICAL_TRIALS trial_result · 2015-08-28Clinical Trial Update: Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes [Phase 3]
A Phase 3 long-term safety study of MP-513 in patients with Type 2 Diabetes Mellitus has completed and posted results. The update summarizes…
-
CLINICAL_TRIALS trial_result · 2015-08-27Clinical Trial Update: Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy [Phase 4]
This Phase 4 clinical trial update reports on the efficacy and safety of insulin glargine in adults with type 2 diabetes inadequately contro…
-
CLINICAL_TRIALS trial_result · 2015-08-27Clinical Trial Update: Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial [Phase 4]
Phase 4 trial update examining cardiovascular safety of thiazolidinediones versus sulphonylureas in patients with type 2 diabetes and cardio…
-
CLINICAL_TRIALS trial_result · 2015-08-27Clinical Trial Update: A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002) [Phase 1]
A Phase 1, single-dose study of MK6349 in patients with Type 2 Diabetes Mellitus was terminated.
-
FDA approval · 2015-08-26FDA Approved: SYNJARDY — Original Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved SYNJARDY (empagliflozin and metformin hydrochloride) as an Original Application for the treatment of type 2 diabetes mellit…
-
CLINICAL_TRIALS trial_result · 2015-08-26Clinical Trial Update: A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus [Phase 4]
A Phase 4 trial comparing Exenatide and Sitagliptin on postprandial glucose in adults with Type 2 Diabetes Mellitus has completed.
-
CLINICAL_TRIALS trial_result · 2015-08-25Clinical Trial Update: PEARL Program: Empowerment Program for Patients With Type 2 Diabetes (HK4) [NA]
A completed clinical trial update for the PEARL program, an empowerment program for patients with Type 2 diabetes in Hong Kong.
-
CLINICAL_TRIALS research · 2015-08-24Clinical Trial Update: Prevalence Study of Depression in Chinese Patients With Type 2 Diabetes (HK13)
This completed observational study assessed how prevalent depression is among Chinese patients with type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2015-08-24Clinical Trial Update: Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy [NA]
This completed clinical trial from The Chinese University of Hong Kong evaluated whether disease-management strategies influence the develop…
-
CLINICAL_TRIALS research · 2015-08-24Clinical Trial Update: Patient Experiences With Injection Needles [NA]
A completed clinical trial investigating patient experiences with injection needles in the management of Type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2015-08-24Clinical Trial Update: JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients [Phase 4]
A Phase 4 trial (JUBILEE) assessing insulin glargine (Lantus) in patients with Type 2 diabetes mellitus in Eastern populations has completed…
-
CLINICAL_TRIALS trial_result · 2015-08-21Clinical Trial Update: The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy [Phase 2]
A Phase 2 clinical trial evaluating the effects of atorvastatin on the nitric oxide system in patients with Type 2 diabetes and nephropathy …
-
CLINICAL_TRIALS withdrawal · 2015-08-21Clinical Trial Update: Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease [Phase 3]
Phase 3 study of fasiglifam (TAK-875) in adults with type 2 diabetes and cardiovascular disease or risk factors was terminated; results were…
-
CLINICAL_TRIALS trial_result · 2015-08-21Clinical Trial Update: Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease [Phase 4]
A Phase 4 clinical trial update indicates that alpha-lipoic acid reduces left ventricular mass in normotensive patients with type 2 diabetes…
-
CLINICAL_TRIALS trial_result · 2015-08-21Clinical Trial Update: Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability [Phase 1]
Phase 1 study evaluating the bioavailability of a fixed-dose combination tablet of empagliflozin and metformin (BI 10773) compared with the …
-
CLINICAL_TRIALS trial_result · 2015-08-20Clinical Trial Update: Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea
A post-marketing surveillance study conducted in Korea assessed treatment-emergent adverse events in patients with type 2 diabetes taking ex…
-
CLINICAL_TRIALS trial_result · 2015-08-20Clinical Trial Update: Effects of Curcumin Supplementation on Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes [Phase 2, Phase 3]
This clinical trial update discusses the effects of curcumin supplementation on lipid profiles and inflammatory markers in patients with typ…
-
CLINICAL_TRIALS trial_result · 2015-08-20Clinical Trial Update: Surgical Treatment in Diabetic Patients With Grade 1 Obesity [NA]
This update notes the completion of a surgical treatment trial in diabetic patients with grade 1 obesity.